Search

UT Southwestern scientists have discovered a molecular origin of Alzheimer’s disease, led national efforts to improve depression treatment, and now are developing gene therapies for children with the rarest of deadly neurological diseases. These are a few of the distinguishing achievements of faculty associated with the Peter O’Donnell Jr. Brain Institute, which is seeking to position UT Southwestern as a national leader in brain research and care.

A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers. The new study, published in Molecular Cell, also revealed a potential biomarker indicating when these drugs, called PARP inhibitors, can be unleashed in the fight against cancer.

The renowned scientific culture at UT Southwestern was a major attraction for Dr. William T. Dauer, an acclaimed physician-investigator in dystonia and Parkinson’s disease who was recruited in a national search to become the inaugural Director of the Peter O’Donnell Jr. Brain Institute.

Parkinson's patients fight disease through boxing course led by UTSW alumnus

Manipulating dose, timing of therapies reduces relapse in cancer mouse models

The Department of Family and Community Medicine endorses the important role of research and scholarly activities in Graduate Medical Education and continuously seeks to promote an active culture of inquiry for faculty, residents, and medical students.

This year’s Ball for Eye Research, an annual gala benefiting sight-saving research in the Department of Ophthalmology, grossed $244,000 as 200 attendees took part in the spring event at the Dallas Country Club.

Hayden Huckaby, Courtney Huckaby, Stephanie Huckaby, Kaley Huckaby, Chelsea Cronin, and Jeremy Cronin are a family of nurses.

A UT Southwestern Simmons Comprehensive Cancer Center study demonstrates that antiviral drugs for hepatitis C reduce liver-related deaths by nearly 50 percent in patients with a history of liver cancer.

UT Southwestern researchers equipped physicians with web-based software that guided them through protocols for screening patients, prescribing treatments, and measuring their progress.